

Oncology Today with Dr Neil Love: Key Presentations on Genitourinary Cancers from the 2021 ASCO Annual Meeting

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following outcomes was reported at ASCO 2021 from the KEYNOTE-564 study evaluating pembrolizumab as postnephrectomy adjuvant therapy for patients with renal cell carcinoma (RCC)?
  - a. A statistically significant improvement in disease-free survival
  - b. No statistically significant improvement in disease-free survival
2. Results presented at ASCO 2021 from the Phase III VISION trial assessing the radioligand lutetium-177-PSMA-617 for patients with metastatic castration-resistant prostate cancer demonstrated benefit in which of the following endpoints?
  - a. Response rate only
  - b. Overall survival only
  - c. Both response rate and overall survival
3. A subgroup analysis of the Phase III CheckMate 9ER study comparing first-line nivolumab and cabozantinib to sunitinib for patients with advanced RCC reported which of the following observations?
  - a. More benefit with nivolumab/cabozantinib among patients with bone metastases
  - b. Less benefit with nivolumab/cabozantinib among patients with bone metastases
4. Which of the following classes of agents best describes belzutifan, under investigation for von Hippel-Lindau syndrome-associated clear cell RCC?
  - a. MET inhibitors
  - b. HIF inhibitors
  - c. VEGFR inhibitors